共 50 条
- [41] Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trialLANCET, 2018, 392 (10165): : 2705 - 2717Sanyal, ArunCharles, Edgar D.Neuschwander-Tetri, Brent A.Loomba, RohitHarrison, Stephen A.Abdelmalek, Manal F.Lawitz, Eric J.Halegoua-DeMarzio, DinaKundu, SudeepNoviello, StephanieLuo, YiChristian, Rose
- [42] Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitisALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (11-12) : 1405 - 1415Safadi, RifaatBraun, MariusFrancis, AdiMilgrom, YaelMassarwa, MuhammadHakimian, DavidHazou, WadiIssachar, AssafHarpaz, ZivitFarbstein, MottiItzhak, InbalLev-Cohain, NaamaBareket-Samish, AvitalSilverman, Michael H.Fishman, Pnina
- [43] Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled studyJOURNAL OF HEPATOLOGY, 2003, 38 (04) : 414 - 418Merat, SMalekzadeh, RSohrabi, MRSotoudeh, MRakhshani, NSohrabpour, AANaserimoghadam, S
- [44] Mitoxantrone in progressive multiple sclerosis:: a placebo-controlled, double-blind, randomised, multicentre trialLANCET, 2002, 360 (9350): : 2018 - 2025Hartung, HPGonsette, RKönig, NKwiecinski, HGuseo, AMorrissey, SPKrapf, HZwingers, T
- [45] Prophylactic ibuprofen in premature infants:: a multicentre, randomised, double-blind, placebo-controlled trialLANCET, 2004, 364 (9449): : 1945 - 1949Van Overmeire, BAllegaert, KCasaer, ADebauche, CDecaluwé, WJespers, AWeyler, JHarrewijn, ILanghendries, JP
- [46] A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitisBMC Pharmacology and Toxicology, 19Melissa PalmerLee JenningsDebra G. SilbergCaleb BlissPatrick Martin
- [47] A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitisBMC PHARMACOLOGY & TOXICOLOGY, 2018, 19Palmer, MelissaJennings, LeeSilberg, Debra G.Bliss, CalebMartin, Patrick
- [48] Positive topline results from a 24-week, randomized, doubleblind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitisJOURNAL OF HEPATOLOGY, 2020, 73 : S114 - S115Harrison, Stephen A.Neff, GuyGuy, CynthiaBashir, MustafaParedes, AngeloFrias, JuanYounes, Ziad H.Trotter, James F.Gunn, Nadege T.Moussa, SamKohli, AnitaNelson, KristenGottwald, MildredChang, WilliamYan, AndrewDepaoli, AlexLing, LeiLieu, Hsiao
- [49] Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trialLANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (05): : 406 - 416Stefan, NorbertRamsauer, MarkusJordan, PaulNowotny, BettinaKantartzis, KonstantinosMachann, JuergenHwang, Jong-HeeNowotny, PeterKahl, SabineHarreiter, JuergenHornemann, SilkeSanyal, Arun J.Stewart, Paul M.Pfeiffer, Andreas F.Kautzky-Willer, AlexandraRoden, MichaelHaering, Hans-UlrichFuerst-Recktenwald, Sabine
- [50] TOCILIZUMAB (TCZ) IS NOT EFFECTIVE FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS (AS): RESULTS OF A PHASE 2, INTERNATIONAL, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 110 - 111Sieper, J.Porter-Brown, B.Thompson, L.Harari, O.Dougados, M.